We are fortunate to have two authors joining us for a discussion of their recent papers included in the ASH 2018 Guidelines for Management of VTE, recently published in Blood Advances.
Lead author Adam Cuker, MD will discuss his paper: American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.
Lead author Daniel Witt, PharmD will discuss his paper: Optimal Management of Anticoagulation Therapy.
Heparin-Induced Thrombocytopenia (HIT)
Heparin-Induced Thrombocytopenia (HIT) is a prothrombotic adverse drug reaction. One third to one-half of cases of HIT are complicated by thrombosis, which may be limb- or life-threatening. Recommendations address screening of asymptomatic patients for HIT, diagnosis and initial management of patients with suspected HIT, treatment of acute HIT, and special situations in patients with acute HIT or a history of HIT, including cardiovascular surgery, percutaneous cardiovascular intervention (PCI), renal replacement therapy, and VTE prophylaxis.
Optimal Management of Anticoagulation Therapy.
Clinicians confront numerous practical issues in optimizing the use of anticoagulants to treat VTE. Anticoagulant therapy is complex and associated with substantial benefits and risks. These guidelines focus on the optimal management of anticoagulant drugs for the prevention and treatment of VTE following the choice of an anticoagulant.
Resources related to these and other topics included in the guidelines updates can be found at: http://www.hematology.org/VTE/